Protocol Ledger

NCT03709680 · Phase II · COMPLETED

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Interventional Phase II clinical trial protocol NCT03709680 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-24 Enrollment: 128 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03709680
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)128 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03709680
Protocol FieldVerified Registry Value
NCT IdentifierNCT03709680
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment128 participants (ACTUAL)
Registered Start Date2019-05-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI